Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ: SGMT )

4.447 -0.123 (-2.69%)
Streaming Delayed Price Updated: 11:41 AM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024
Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024 
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Leadership Changes
From Sagimet Biosciences Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.